Dr Sarris et al are veterans of kava research and definetely know what they are doing. We have every reason to suspect that Sarris wants kava to succeed (he's joined Fiji Kava Ltd as their scientific advisor) and yet his new flash, well funded study failed to prove that kava can indeed reduce long term anxiety. See the paper here: https://www.ncbi.nlm.nih.gov/pubmed/31813230 I have a couple small issues with this study. 1. 120mg of kavalactones is a fairly small dose. a small shell of weak kava. 2. The participants were supposedly consuming booze while "under treatment ". This may explain the liver abnormalities, but generally I am shocked this isn't considered as a big variable that might have affected the results of this study. But in general the conculsion of this study is not necessarily bad or even at odds with my own personal take on kava: "While extant data show that standardised Kava (containing either 120, 240 or 250mg of kavalactones) is an effective short-term treatment for generalised and, potentially more so, ‘situational’ anxiety, the results of our study indicate that it is not effective as a psychotropic medication for diagnosed GAD. Aside from Kava’s valued social, cultural and recreational use, based on our findings and previous data, the plant’s therapeutic application may more appropriately extend to its use as an anxiolytic prior to a potential situational anxiogenic event, or for intermittent use in the additional management of non-clinical anxiety and stress."